Overview
This guideline covers mental health rehabilitation for adults with complex psychosis. It aims to ensure people can have rehabilitation when they need it and promotes a positive approach to long-term recovery. It includes recommendations on organising rehabilitation services, assessment and care planning, delivering programmes and interventions, and meeting people’s physical healthcare needs.
NICE has also produced guidelines on psychosis and schizophrenia in adults and bipolar disorder.
The recommendations in this guideline were developed before the coronavirus pandemic.
Anti-epileptic medicines: Follow the Medicines and Healthcare products Regulatory Agency (MHRA) safety advice on the use of valproate, valproate use in people younger than 55 years, valproate use in women and girls, valproate use in men and anti-epileptic drugs in pregnancy.
Last reviewed: 16 August 2024
We simplified the guideline by removing recommendations on general principles of care that are covered in other NICE guidelines (for example, the NICE guideline on service user experience in adult mental health). This is a presentational change only, and no changes to practice are intended.
Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.
Recommendations
This guideline includes recommendations on:
- who should be offered rehabilitation
- principles of rehabilitation
- organising the rehabilitation pathway, improving access and delivering services
- a recovery-orientated approach
- assessment, care planning and review
- programmes and interventions
- adjustments to mental health treatments in rehabilitation
- physical healthcare
Who is it for?
- Healthcare professionals
- Social care practitioners and other practitioners providing public services for people with complex psychosis
- Commissioners and providers of mental health services
- People using mental health services, their families and carers
Guideline development process
How we develop NICE guidelines
Your responsibility
The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian.
All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.
Local commissioners and providers of healthcare have a responsibility to enable the guideline to be applied when individual professionals and people using services wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.